MacuLogix Stock
Detecting and tracking age-related macular degeneration
Sign up today and learn more about MacuLogix Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About MacuLogix Stock
MacuLogix aims to detect early and track age-related macular degeneration (AMD). MacuLogix’ AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD.
Funding History
| July 2012 | $2.9M |
|---|---|
| March 2013 | $3.6M |
| June 2014 | $3.6M |
| October 2015 | $5.0M |
| July 2018 | $10.0M |
| March 2019 | $38.7M |
Management
Co-founder and Chief Scientific Officer
Gregory R. Jackson
CEO
Bill McPhee
Press
prnewswire - Jul, 26 2022
LumiThera, Inc. Announces Purchase of MacuLogix Assetsnewswire - Jan, 18 2020
MacuLogix Introduces the AdaptDx Pro, Guided by Theianewswire - Nov, 15 2019
MacuLogix Hires Christine W. Silverberg as Director of National Accountsnewswire - Oct, 23 2019
'Practical Strategies for Preventing Blindness Caused by AMD' Offers Clear Framework on How to Manage AMD in Optometric Practicefinsmes - Sep, 29 2015
MacuLogix Raises $3.6M in Series A FundingEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
